search
Back to results

Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation (45RA_NEG_DLI)

Primary Purpose

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Immune Deficiency Disease

Status
Completed
Phase
Phase 1
Locations
Russian Federation
Study Type
Interventional
Intervention
CD45RA-depleted peripheral blood mononuclear cells
Sponsored by
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Precursor T-Cell Lymphoblastic Leukemia-Lymphoma focused on measuring CD45RA-depletion, TCR-alpha/beta depletion, Hematopoietic Stem Cell Transplantation, immune reconstitution, Graft Enhancement, Immunologic, Immunocompromized Host

Eligibility Criteria

undefined - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • recipient of allogeneic hematopoietic stem cell graft from haploidentical or matched unrelated donor
  • TCR alpha/beta depletion of the hematopoietic stem cell graft
  • CMV-seropositive donor
  • stable hematopoietic engraftment

Exclusion Criteria:

  • active graft-versus-host disease grade 2-4
  • any systemic immune suppressive therapy except calcineurin inhibitor monotherapy
  • uncontrolled sepsis

Sites / Locations

  • Federal Research Center for pediatric hematology, oncology and immunology

Outcomes

Primary Outcome Measures

Cumulative incidence of grade 2-4 acute graft-versus-host disease
Cumulative incidence (competing risk model) of acute graft-versus-host disease
Immune reconstitution (Quantitative evaluation of lymphocyte subsets in the peripheral blood, quantitative evaluation of pathogen-specific immune response by ELISPOT assay)
Quantitative evaluation of lymphocyte subsets in the peripheral blood, quantitative evaluation of pathogen-specific immune response by ELISPOT assay

Secondary Outcome Measures

1-year survival
Kaplan-Meyer estimate of overall survival
Transplant-related mortality
Cumulative incidence (competing risk model) of transplant-related mortality
Incidence of chronic graft-versus-host disease
Cumulative incidence (competing risk model) of chronic graft-versus-host disease

Full Information

First Posted
January 9, 2015
Last Updated
April 21, 2016
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
search

1. Study Identification

Unique Protocol Identification Number
NCT02337595
Brief Title
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
Acronym
45RA_NEG_DLI
Official Title
Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
January 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The stud will evaluate whether infusions of CD45RA-depleted lymphocytes from the donor early post-transplant is a safe way to improve immunity to common infections in recipients of TCR-alpha/beta depleted hematopoietic stem cell grafts.
Detailed Description
Graft-versus-host disease (GVHD) remains the most important direct complication of hematopoietic stem cell transplantation. Methods used to prevent GVHD include diverse pharmacologic interventions and ex vivo methods of T-cell depletion, the latter being the most effective ones. Historically depletion of T-cells from the graft is associated with increased rate of graft failure, relapse of malignant disease and prolonged immune deficiency. Selective depletion of TCR-alpha/beta T-lymphocytes is a new method of hematopoietic stem cell graft manipulation which is thought to conserve important cell populations, e.g. NK cells and gamma/delta T cells within the graft. Preliminary results suggest that TCR alpha/beta depletion ensures high engraftment rate, low early mortality and good control of GVHD. The problem of delayed immune reconstitution and life-threatening viral infections remains incompletely resolved. Depletion of naive (CD45RA-positive) T-cells was developed as a new method of graft manipulation to prevent GVHD. Research data indicate that alloreactivity is associated mainly with naive T-cell fraction. In vitro depletion of CD45RA lowers significantly the alloreactive response while retaining reactivity to pathogens. In the current protocol we plan to test whether relatively low doses of CD45RA-depleted mononuclear cells can be safely infused after TCR-alpha/beta depleted transplantation. The biologic readout for the protocol will be quantitative assessment of T-cell reactivity to common pathogens after infusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Immune Deficiency Disease, Bone Marrow Failure Syndromes, Opportunistic Infections, Graft vs Host Disease
Keywords
CD45RA-depletion, TCR-alpha/beta depletion, Hematopoietic Stem Cell Transplantation, immune reconstitution, Graft Enhancement, Immunologic, Immunocompromized Host

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Biological
Intervention Name(s)
CD45RA-depleted peripheral blood mononuclear cells
Intervention Description
Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
Primary Outcome Measure Information:
Title
Cumulative incidence of grade 2-4 acute graft-versus-host disease
Description
Cumulative incidence (competing risk model) of acute graft-versus-host disease
Time Frame
100 days
Title
Immune reconstitution (Quantitative evaluation of lymphocyte subsets in the peripheral blood, quantitative evaluation of pathogen-specific immune response by ELISPOT assay)
Description
Quantitative evaluation of lymphocyte subsets in the peripheral blood, quantitative evaluation of pathogen-specific immune response by ELISPOT assay
Time Frame
120 days
Secondary Outcome Measure Information:
Title
1-year survival
Description
Kaplan-Meyer estimate of overall survival
Time Frame
1 year
Title
Transplant-related mortality
Description
Cumulative incidence (competing risk model) of transplant-related mortality
Time Frame
1-year
Title
Incidence of chronic graft-versus-host disease
Description
Cumulative incidence (competing risk model) of chronic graft-versus-host disease
Time Frame
1 year

10. Eligibility

Sex
All
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: recipient of allogeneic hematopoietic stem cell graft from haploidentical or matched unrelated donor TCR alpha/beta depletion of the hematopoietic stem cell graft CMV-seropositive donor stable hematopoietic engraftment Exclusion Criteria: active graft-versus-host disease grade 2-4 any systemic immune suppressive therapy except calcineurin inhibitor monotherapy uncontrolled sepsis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Maschan, MD
Organizational Affiliation
Fedaral Research Center for pediatric hematology, oncology and immunology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Federal Research Center for pediatric hematology, oncology and immunology
City
Moscow
ZIP/Postal Code
117997
Country
Russian Federation

12. IPD Sharing Statement

Citations:
PubMed Identifier
23933765
Citation
Teschner D, Distler E, Wehler D, Frey M, Marandiuc D, Langeveld K, Theobald M, Thomas S, Herr W. Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis. Bone Marrow Transplant. 2014 Jan;49(1):138-44. doi: 10.1038/bmt.2013.114. Epub 2013 Aug 12.
Results Reference
background
PubMed Identifier
24525279
Citation
Bleakley M, Heimfeld S, Jones LA, Turtle C, Krause D, Riddell SR, Shlomchik W. Engineering human peripheral blood stem cell grafts that are depleted of naive T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant. 2014 May;20(5):705-16. doi: 10.1016/j.bbmt.2014.01.032. Epub 2014 Feb 11.
Results Reference
background

Learn more about this trial

Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation

We'll reach out to this number within 24 hrs